|
|
| Line 3: |
Line 3: |
| | {{dgfn2015 Sa Opening - On the comparative physiology of men, mice and bears}} | | {{dgfn2015 Sa Opening - On the comparative physiology of men, mice and bears}} |
| | {{dgfn2015 So 7:00 Hyperuricemia}} | | {{dgfn2015 So 7:00 Hyperuricemia}} |
| − | {{dgfn2015 }} | + | {{dgfn2015 Mo 7:00 PCSK9}} |
| | {{dgfn2015 }} | | {{dgfn2015 }} |
| | {{dgfn2015 }} | | {{dgfn2015 }} |
Revision as of 12:55, 14 September 2015
There are quite a lot of citations, data on - paper. Lets start with the Hyperuricemia lecture from so 7:00
Sa Opening - On the comparative physiology of men, mice and bears
sorry no citations collected
So 7:00 Hyperuricemia
Extra paper fresh from nephroVIP twitter
| Journal article, free access
|
| GET 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Extract PDF direct
|
| Journal article, free access
|
| GET Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial Extract PDF direct
|
| Journal article, free access
|
| GET Uric acid and chronic kidney disease: which is chas ing which? Extract PDF direct
|
| Journal article, free access
|
| GET A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population Extract PDF direct
|
| Journal article, free access
|
| GET Uric acid and incident kidney disease in the community Extract PDF direct
|
| Journal article, free access
|
| GET Elevated uric acid increases the risk for kidney disease Extract PDF direct
|
| Journal article, free access
|
| GET Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study Extract PDF direct
|
| Journal article, free access
|
| GET Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study Extract PDF direct
|
| Journal article, free access
|
| GET High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up Extract PDF direct
|
| Journal article, free access
|
| GET Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia Extract PDF direct
|
- ndt 2015;..:1 doi10.1693/ndt/gfv222 wrong citation
| Journal article, free access
|
| GET Febuxostat compared with allopurinol in patients with hyperuricemia and gout Extract PDF direct
|
| Journal article, free access
|
| GET Effect of allopurinol in chronic kidney disease progression and cardiovascular risk Extract PDF direct
|
| Journal article, free access
|
| GET Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial Extract PDF direct
|
| Journal article, free access
|
| GET Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial Extract PDF direct
|
| Journal article, free access
|
| GET The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study Extract PDF direct
|
| Journal article, free access
|
| GET Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis Extract PDF direct
|
| Journal article, free access
|
| GET Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis Extract PDF direct
|
| Journal article, free access
|
| GET The independent association between serum uric acid and graft outcomes after kidney transplantation Extract PDF direct
|
- wrong cit jasn 2009 4 1655
| Journal article, free access
|
| GET Effects of hyperuricemia on renal function of renal transplant recipients: a systematic review and meta-analysis of cohort studies Extract PDF direct
|
| Journal article, free access
|
| GET Uric acid: a novel risk factor for acute kidney injury in high-risk cardiac surgery patients? Extract PDF direct
|
- missing citation j urol 2002
| Journal article, free access
|
| GET Metabolic basis for low urine pH in type 2 diabetes Extract PDF direct
|
| Journal article, free access
|
| GET Gout, stone composition and urinary stone risk: a matched case comparative study Extract PDF direct
|
| Journal article, free access
|
| GET Randomized trial of allopurinol in the prevention of calcium oxalate calculi Extract PDF direct
|
| Journal article, free access
|
| GET Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones Extract PDF direct
|
| Journal article, free access
|
| GET Kidney stones and the risk for chronic kidney disease Extract PDF direct
|
eof.
DGFN2015 Neue Wirkansätze in der Hyperlipidämie - Stellenwert für die Nephrologie (Rump-LC,Gouni-Berthold-I)
Session Videos
Lipidmanagement bei CKD-Patienten, Was ist belegt, was zu beachten. (Wanner-W)
| Journal Paper, restricted access
|
| GET A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates Extract PDF direct
|
| Journal Paper, restricted access
|
| GET The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Extract PDF direct
|
PCSK9-Inhibitoren: ein neuer Wirkmechanismus (Schettler-V)
| Journal Paper, restricted access
|
| GET A century of cholesterol and coronaries: from plaques to genes to statins Extract PDF direct
|
| Journal Paper, restricted access
|
| GET The biology and therapeutic targeting of the proprotein convertases Extract PDF direct
|
| Journal article, free access
|
| GET Plasma membrane CD81 complexes with PCSK9 and LDLR and its levels are reduced by PCSK9 Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Protease variants, LDL, and coronary heart disease Extract PDF direct
|
| Journal article, free access
|
| GET Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis Extract PDF direct
|
| Journal article, free access
|
| GET Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease Extract PDF direct
|
| Journal article, free access
|
| GET Sequence variations in PCSK9, low LDL, and protection against coronary heart disease Extract PDF direct
|
| Journal article, free access
|
| GET Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study Extract PDF direct
|
| Journal article, free access
|
| GET The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Antihyperlipidemic therapies targeting PCSK9 Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Pharmacotherapies for lipid modification: beyond the statins Extract PDF direct
|
| Journal article, free access
|
| GET Lipids and CVD management: towards a global consensus Extract PDF direct
|
| Journal article, free access
|
| GET High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Extract PDF direct
|
| Journal Paper, restricted access
|
| GET The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe Extract PDF direct
|
| Journal article, free access
|
| GET A 52-week placebo-controlled trial of evolocumab in hyperlipidemia Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Extract PDF direct
|
| Journal article, free access
|
| GET AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Lipoprotein(a) mass: a massively misunderstood metric Extract PDF direct
|
| Journal article, free access (Hinweis: wrong paper ??? 2015;15:41 Schettler)
|
| GET Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels Extract PDF direct
|
| Journal article, free access
|
| GET Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis Extract PDF direct
|
Was kommt nach den Statinen ? Aktuelles zu PCSK9 Antikörpern (König-W)
| Journal article, free access
|
| GET Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Meta-analysis of comparative efficacy of increas.ing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Extract PDF direct
|
| Journal Paper, restricted access
|
| GET Efficacy and safety of evolocumab in reducing lipids and cardiovascular events Extract PDF direct
|
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
Template:Dgfn2015
